{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T19:10:35Z","timestamp":1759777835485,"version":"3.37.3"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>A new 1\u03b1,25-dihydroxy vitamin D3 analog (2-methylene-22(E)-(24R)-22-dehydro-1\u03b1,24,25-trihydroxy-19-norvitamin D3 or WT-51) has been tested as a possible therapeutic for osteoporosis. It is 1\/10th as active as 1,25(OH)2D3 in binding affinity for the vitamin D receptor but is at least 200 times more active than 1,25(OH)2D3 and equal to that of 2MD (2-methylene-19-nor-(20S)-1\u03b1,25(OH)2D3, an analog previously tested in postmenopausal women), in supporting bone formation by isolated osteoblasts in culture. However, in contrast to 2MD, it is virtually inactive on bone resorption in vivo. WT-51 markedly increased bone mass (lumbar and femur) in ovariectomized (OVX) female rats. Further, bone strength tested by the three-point bending system is significantly increased by WT-51. Thus, WT-51 is an attractive candidate for the treatment of postmenopausal osteoporosis. \u00a9 2019 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.3838","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T14:54:50Z","timestamp":1564671290000},"page":"623-630","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A New 1,25 Dihydroxy Vitamin D Analog with Strong Bone Anabolic Activity in OVX Rats with Little or no Bone Resorptive Activity"],"prefix":"10.1093","volume":"35","author":[{"given":"Lori A","family":"Plum","sequence":"first","affiliation":[{"name":"Department of Biochemistry University of Wisconsin\u2013Madison Madison WI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Zella","sequence":"additional","affiliation":[{"name":"Department of Biochemistry University of Wisconsin\u2013Madison Madison WI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Clagett-Dame","sequence":"additional","affiliation":[{"name":"Department of Biochemistry University of Wisconsin\u2013Madison Madison WI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3928-3303","authenticated-orcid":false,"given":"Hector F","family":"DeLuca","sequence":"additional","affiliation":[{"name":"Department of Biochemistry University of Wisconsin\u2013Madison Madison WI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"key":"2024031418590378400_jbmr3838-bib-0001","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11914-014-0242-z","article-title":"Osteoporosis diagnosis in men: the T-score controversy revisited","volume":"12","author":"Binkley","year":"2014","journal-title":"Curr Osteoporos Rep"},{"key":"2024031418590378400_jbmr3838-bib-0002","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N Engl J Med."},{"issue":"3","key":"2024031418590378400_jbmr3838-bib-0003","doi-asserted-by":"crossref","first-page":"133","DOI":"10.11005\/jbm.2018.25.3.133","article-title":"Treatment of osteoporosis: unmet needs and emerging solutions","volume":"25","author":"Langdahl","year":"2018","journal-title":"J Bone Metab"},{"key":"2024031418590378400_jbmr3838-bib-0004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.maturitas.2017.04.008","article-title":"Drug holidays form bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement","volume":"101","author":"Anagnostis","year":"2017","journal-title":"Maturitas."},{"issue":"7","key":"2024031418590378400_jbmr3838-bib-0005","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1177\/0192623317737066","article-title":"Antiresorptives: safety concerns-clinical perspective","volume":"45","author":"Brown","year":"2017","journal-title":"Toxicol Pathol."},{"issue":"8","key":"2024031418590378400_jbmr3838-bib-0006","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1210\/js.2018-00118","article-title":"Osteoanabolic agents for osteoporosis","volume":"2","author":"Haas","year":"2018","journal-title":"J Endocr Soc."},{"issue":"12","key":"2024031418590378400_jbmr3838-bib-0007","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1056\/NEJM199003223221203","article-title":"Effect of flouride treatment on the fracture rate in postmenopausal women with osteoporosis","volume":"322","author":"Riggs","year":"1990","journal-title":"N Engl J Med"},{"key":"2024031418590378400_jbmr3838-bib-0008","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s001980050041","article-title":"Flouride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVO study","volume":"8","author":"Meunier","year":"1998","journal-title":"Osteoporos Int."},{"issue":"2","key":"2024031418590378400_jbmr3838-bib-0009","first-page":"3015","article-title":"Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1 alpha-OHD3) 1,24 Dihydroxycholecalciferol (1,24(OH)2D3)","volume":"32","author":"Shiracki","year":"1985","journal-title":"Endocrinol Jpn."},{"key":"2024031418590378400_jbmr3838-bib-0010","first-page":"47","article-title":"Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3","volume":"3","author":"Orimo","year":"1987","journal-title":"Bone Miner"},{"issue":"6","key":"2024031418590378400_jbmr3838-bib-0011","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199202063260601","article-title":"Treatment of postmenopausal osteoporosis with calcitriol or calcium","volume":"326","author":"Tilyard","year":"1992","journal-title":"N Engl J Med."},{"key":"2024031418590378400_jbmr3838-bib-0012","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12020-015-0606-x","article-title":"The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF)","volume":"50","author":"Cianferotti","year":"2015","journal-title":"Endocrine."},{"issue":"4","key":"2024031418590378400_jbmr3838-bib-0013","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00198-007-0490-1","article-title":"Salmon calcitonin: a review of current and future therapeutic indications","volume":"19","author":"Chestnut","year":"2008","journal-title":"Osteoporos Int"},{"issue":"7","key":"2024031418590378400_jbmr3838-bib-0014","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMoa053569","article-title":"Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis","volume":"355","author":"de Nijs","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"2024031418590378400_jbmr3838-bib-0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","article-title":"Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis","volume":"148","author":"MacLean","year":"2008","journal-title":"Ann Intern Med"},{"issue":"4","key":"2024031418590378400_jbmr3838-bib-0016","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S8756-3282(02)00682-8","article-title":"ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis","volume":"30","author":"Uchiyama","year":"2002","journal-title":"Bone"},{"issue":"8","key":"2024031418590378400_jbmr3838-bib-0017","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1359\/jbmr.2002.17.8.1498","article-title":"Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1alpha,25-dihydroxyvitamin D3","volume":"17","author":"Erben","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024031418590378400_jbmr3838-bib-0018","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1210\/en.2006-0403","article-title":"Exogenous 1,25-dihydroxyvitamin D3 exerts a skeletal anabolic effect and improves mineral ion homeostasis in mice that are homozygous for both the l\u03b1-hydrosylase and parathyroid hormone null alleles","volume":"147","author":"Xue","year":"2006","journal-title":"Endocrinology"},{"issue":"21","key":"2024031418590378400_jbmr3838-bib-0019","doi-asserted-by":"crossref","first-page":"13487","DOI":"10.1073\/pnas.202471299","article-title":"A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation","volume":"99","author":"Shevde","year":"2002","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"10","key":"2024031418590378400_jbmr3838-bib-0020","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1359\/JBMR.050605","article-title":"A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia","volume":"20","author":"Ke","year":"2005","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2024031418590378400_jbmr3838-bib-0021","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00198-005-0036-3","article-title":"2MD, a new anabolic agent for osteoporosis treatment","volume":"17","author":"Plum","year":"2006","journal-title":"Osteoporos Int."},{"issue":"3","key":"2024031418590378400_jbmr3838-bib-0022","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/jbmr.256","article-title":"The vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: results of a 1-year phase 2 double-blind, placebo-controlled, randomized clinical trial","volume":"26","author":"DeLuca","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024031418590378400_jbmr3838-bib-0023","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1021\/jm051082a","article-title":"New 2-alkylidene 1alpha,25-dihydroxy-19-norvitamin D3 analogues of high intestinal activity: synthesis and biological evaluation of 2-(3\u2032-alkoxypropylidene) and 2-(3\u2032-hydroxypropylidene) derivatives","volume":"49","author":"Glebocka","year":"2006","journal-title":"J Med Chem."},{"key":"2024031418590378400_jbmr3838-bib-0024","volume-title":"Staining procedures","author":"Clark","year":"1981","edition":"4th ed."},{"key":"2024031418590378400_jbmr3838-bib-0025","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/jn\/100.9.1049","article-title":"Biological activity of 25-hydroxyergocalciferol in rats","volume":"100","author":"Suda","year":"1970","journal-title":"J Nutr"},{"issue":"23","key":"2024031418590378400_jbmr3838-bib-0026","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1021\/jm9802618","article-title":"New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues","volume":"41","author":"Sicinski","year":"1998","journal-title":"J Med Chem"},{"key":"2024031418590378400_jbmr3838-bib-0027","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF02058664","article-title":"Tetracycline-based histological analysis of bone remodeling","volume":"3","author":"Frost","year":"1969","journal-title":"Calcif Tissue Res"},{"issue":"5","key":"2024031418590378400_jbmr3838-bib-0028","first-page":"424","article-title":"The laboratory rat as an animal model for osteoporosis research","volume":"58","author":"Lelovas","year":"2008","journal-title":"Comp Med"},{"issue":"1","key":"2024031418590378400_jbmr3838-bib-0029","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00774-014-0643-1","article-title":"Combination therapy with ONO-KK1-300-01, a cathepsin K inhibitor, and parathyroid hormone results in additive beneficial effect on bone mineral density in ovariectomized rats","volume":"34","author":"Ochi","year":"2016","journal-title":"J Bone Miner Metab"},{"key":"2024031418590378400_jbmr3838-bib-0030","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41574-018-0087-0","article-title":"Clinical advantages and disadvantages of anabolic bone terapies targeting the WNT pathway","volume":"14","author":"Appelman-Dijkstra","year":"2018","journal-title":"Nat Rev Endocrinol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.3838","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.3838","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.3838","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/35\/4\/623\/55453609\/jbmr3838.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/35\/4\/623\/55453609\/jbmr3838.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T19:01:46Z","timestamp":1710442906000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/35\/4\/623\/7516476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3838","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"type":"print","value":"0884-0431"},{"type":"electronic","value":"1523-4681"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2019,8,1]]},"assertion":[{"value":"2019-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}